EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
EyePoint (Nasdaq: EYPT) will report fourth-quarter and full-year 2025 results and host a conference call and live webcast at 8:30 a.m. ET on March 4, 2026.
Rhea-AI Summary
EyePoint (Nasdaq: EYPT) will report fourth-quarter and full-year 2025 results and host a conference call and live webcast at 8:30 a.m. ET on March 4, 2026. The event will include a review of financial results and recent corporate developments.
According to the company, registration is required for the audio conference and a live webcast plus replay will be available on the company's investor website.
Details
News Market Reaction – EYPT
On Feb 25, the day this news came out, EYPT closed 4.16% above the previous close.
Data tracked by StockTitan Argus for the Feb 25 session.
Key Figures
- Earnings call date
- March 4, 2026
- Scheduled conference call and webcast for Q4 and full-year 2025 results
- Earnings call time
- 8:30 a.m. ET
- Start time of EyePoint’s Q4 and full-year 2025 results call
- Reporting period
- Fourth quarter 2025
- Financial results to be discussed on March 4, 2026 call
- Reporting period
- Full-year 2025
- Financial results to be discussed on March 4, 2026 call
Historical Context
-
Participation in four March 2026 investor conferences with webcast access.
-
Appointment of Chief Commercial Officer to lead DURAVYU Phase 3 launch readiness.
-
Nasdaq Rule 5635(c)(4) option inducement awards totaling 143,000 shares.
-
CFO fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026.
-
Inducement stock options for new employees under Nasdaq Rule 5635(c)(4).
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to report its fourth quarter and full-year 2025 financial results and highlight recent corporate developments.
To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/i8pzi8wg. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepoint.bio. A webcast replay will also be available on the Company website at the conclusion of the call.
About EyePoint
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration with expected topline data beginning in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema is expected in the first quarter of 2026.
The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com
Media Contact:
Green Room Communications
Direct: 850-384-2833
EyePointMedia@grcomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.